FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2982206949> ?p ?o ?g. }

• W2982206949 endingPage "S768" @default.
• W2982206949 startingPage "S768" @default.
• W2982206949 abstract "Abstract Background Outcomes are improved with ceftazidime–avibactam (CZA) compared with polymyxin-based regimens (PBR) for carbapenemase-producing carbapenem-resistant Enterobacteriaceae. It is unclear whether this finding is true in non-carbapenemase (non-CP) producing CRE. The purpose of this study was to compare the efficacy and safety of CZA-based and PBR for CRE bacteremia in cancer patients with a high prevalence of non-CP CRE. Methods Adult cancer patients with first occurrence of CRE (i.e., meropenem non-susceptible) bacteremia treated with either CZA or PBR as directed therapy were included. Day 14 integrated benefit-risk outcomes based on desirability of outcome ranking (DOOR; (1) cured and discharged home, (2) cured and hospitalized, (3) cured and hospitalized with renal failure, (4) not cured, (5) dead) were used. DOOR is a recently developed statistical approach designed to unify important patient and clinician outcomes. Inverse probability of treatment weighted (IPTW) ordered logistic regression was used to model the odds of moving down ranked DOOR categories (i.e., having a worse outcome). The probability of a patient treated with CZA or a PBR having a worse DOOR category was also calculated. IPTW logistic regression was used to model the odds of 14-day mortality. Results 43 patients (CZA, n = 24; PBR, n = 19) with similar demographics and relative illness were included. Klebsiella pneumoniae (n = 21) and Escherichia coli (n = 16) were most common. 16/43 (37%) were CP CRE, 19/43 (44%) were non-CP CRE, and the remainder were unknown. The probability of a better DOOR for patients treated with CZA was 58% (95% CI 53% - 62%). Patients treated with CZA had an 81% reduction in IPTW-adjusted odds of a worse DOOR (OR 0.19, 95% CI 0.05 – 0.76; P = 0.02). 14-day mortality was 2/24 (8%) for patients receiving CZA vs. 5/19 (26%) for patients treated with PBR (IPTW-adjusted OR 0.12, 95% CI 0.02 – 0.82, P = 0.03). Conclusion These data suggest that CZA-based treatment, compared with PBR, has a superior integrated benefit-risk profile for the treatment of CRE bacteremia in cancer patients with a high burden of non-CP CRE. These findings build upon available data and suggest that CZA is preferred to PBR for CRE with heterogenous resistance mechanisms. Disclosures Samuel L. Aitken, PharmD, Melinta Therapeutoics: Grant/Research Support, Research Grant; Merck, Sharpe, and Dohme: Advisory Board; Shionogi: Advisory Board." @default.
• W2982206949 created "2019-11-01" @default.
• W2982206949 creator A5080337533 @default.
• W2982206949 creator A5089378249 @default.
• W2982206949 creator A5091033255 @default.
• W2982206949 creator A5091663701 @default.
• W2982206949 date "2019-10-01" @default.
• W2982206949 modified "2023-09-25" @default.
• W2982206949 title "2246. Improved Outcomes for Cancer Patients Treated With Ceftazidime–Avibactam vs. Polymyxin-Containing Regimens for Carbapenem-Resistant Enterobacteriaceae Bacteremia" @default.
• W2982206949 doi "https://doi.org/10.1093/ofid/ofz360.1924" @default.
• W2982206949 hasPublicationYear "2019" @default.
• W2982206949 type Work @default.
• W2982206949 sameAs 2982206949 @default.
• W2982206949 citedByCount "1" @default.
• W2982206949 countsByYear W29822069492021 @default.
• W2982206949 crossrefType "journal-article" @default.
• W2982206949 hasAuthorship W2982206949A5080337533 @default.
• W2982206949 hasAuthorship W2982206949A5089378249 @default.
• W2982206949 hasAuthorship W2982206949A5091033255 @default.
• W2982206949 hasAuthorship W2982206949A5091663701 @default.
• W2982206949 hasBestOaLocation W29822069491 @default.
• W2982206949 hasConcept C104317684 @default.
• W2982206949 hasConcept C126322002 @default.
• W2982206949 hasConcept C141071460 @default.
• W2982206949 hasConcept C151956035 @default.
• W2982206949 hasConcept C156957248 @default.
• W2982206949 hasConcept C177713679 @default.
• W2982206949 hasConcept C2775933652 @default.
• W2982206949 hasConcept C2775992322 @default.
• W2982206949 hasConcept C2776685102 @default.
• W2982206949 hasConcept C2776968632 @default.
• W2982206949 hasConcept C2777058267 @default.
• W2982206949 hasConcept C2777637488 @default.
• W2982206949 hasConcept C2779443120 @default.
• W2982206949 hasConcept C501593827 @default.
• W2982206949 hasConcept C523546767 @default.
• W2982206949 hasConcept C54355233 @default.
• W2982206949 hasConcept C547475151 @default.
• W2982206949 hasConcept C55493867 @default.
• W2982206949 hasConcept C71924100 @default.
• W2982206949 hasConcept C86803240 @default.
• W2982206949 hasConcept C89423630 @default.
• W2982206949 hasConceptScore W2982206949C104317684 @default.
• W2982206949 hasConceptScore W2982206949C126322002 @default.
• W2982206949 hasConceptScore W2982206949C141071460 @default.
• W2982206949 hasConceptScore W2982206949C151956035 @default.
• W2982206949 hasConceptScore W2982206949C156957248 @default.
• W2982206949 hasConceptScore W2982206949C177713679 @default.
• W2982206949 hasConceptScore W2982206949C2775933652 @default.
• W2982206949 hasConceptScore W2982206949C2775992322 @default.
• W2982206949 hasConceptScore W2982206949C2776685102 @default.
• W2982206949 hasConceptScore W2982206949C2776968632 @default.
• W2982206949 hasConceptScore W2982206949C2777058267 @default.
• W2982206949 hasConceptScore W2982206949C2777637488 @default.
• W2982206949 hasConceptScore W2982206949C2779443120 @default.
• W2982206949 hasConceptScore W2982206949C501593827 @default.
• W2982206949 hasConceptScore W2982206949C523546767 @default.
• W2982206949 hasConceptScore W2982206949C54355233 @default.
• W2982206949 hasConceptScore W2982206949C547475151 @default.
• W2982206949 hasConceptScore W2982206949C55493867 @default.
• W2982206949 hasConceptScore W2982206949C71924100 @default.
• W2982206949 hasConceptScore W2982206949C86803240 @default.
• W2982206949 hasConceptScore W2982206949C89423630 @default.
• W2982206949 hasIssue "Supplement_2" @default.
• W2982206949 hasLocation W29822069491 @default.
• W2982206949 hasLocation W29822069492 @default.
• W2982206949 hasOpenAccess W2982206949 @default.
• W2982206949 hasPrimaryLocation W29822069491 @default.
• W2982206949 hasRelatedWork W2483207560 @default.
• W2982206949 hasRelatedWork W2618911885 @default.
• W2982206949 hasRelatedWork W2792380978 @default.
• W2982206949 hasRelatedWork W2946890307 @default.
• W2982206949 hasRelatedWork W2971663956 @default.
• W2982206949 hasRelatedWork W2975061016 @default.
• W2982206949 hasRelatedWork W2981943845 @default.
• W2982206949 hasRelatedWork W3095228502 @default.
• W2982206949 hasRelatedWork W3111122494 @default.
• W2982206949 hasRelatedWork W4210756530 @default.
• W2982206949 hasVolume "6" @default.
• W2982206949 isParatext "false" @default.
• W2982206949 isRetracted "false" @default.
• W2982206949 magId "2982206949" @default.
• W2982206949 workType "article" @default.